0.4918

1.42% -0.0071

After Hours: .4761 -0.0157 -3.19%

BioVie Inc (BIVI)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

BioVie Inc stock is currently priced at $0.4918, with a 24-hour trading volume of 217.54K. It has seen a -1.42% decreased in the last 24 hours and a +4.33% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.496 pivot point. If it approaches the $0.4844 support level, significant changes may occur.

Previous Close:

$0.4989

Open:

$0.4912

24h Volume:

217.54K

Market Cap:

$27.01M

Revenue:

Net Income/Loss:

$-43.27M

P/E Ratio:

-0.3194

EPS:

-1.54

Net Cash Flow:

$-41.11M

1W Performance:

+1.15%

1M Performance:

+4.33%

6M Performance:

-87.86%

1Y Performance:

-93.15%

1D Range:

$0.4883

$0.4999

52W Range:

$0.445

$7.6327

BioVie Inc Stock (BIVI) Company Profile

Name

BioVie Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

312 283 5793

Address

2120 Colorado Avenue, Suite 230, Santa Monica

Employee

Twitter

Next Earnings Date

2024-05-27

Latest SEC Filings

BIVI's Discussions on Twitter

BioVie Inc Stock (BIVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-22	Initiated	Cantor Fitzgerald	Overweight
Jan-15-21	Initiated	B. Riley Securities	Buy

BioVie Inc Stock (BIVI) Latest News

BioVie Inc (BIVI)'s stock price range in the last year – US Post News - US Post News

US Post News

Wall Street Analysts Think BioVie Inc. (BIVI) Could Surge 84%: Read This Before Placing a Bet - Yahoo New Zealand News

Yahoo New Zealand News

Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround - Yahoo New Zealand News

Yahoo New Zealand News

Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI) - Yahoo News UK

Yahoo News UK

BioVie Inc (BIVI) deserves deeper analysis – US Post News - US Post News

US Post News

BioVie receives $13.1 million DOD grant for long COVID trial - Investing.com

Investing.com

BioVie Inc Stock (BIVI) Financials Data

BioVie Inc (BIVI) Net Income 2024

BIVI net income (TTM) was -$43.27 million for the quarter ending December 31, 2023, a -4.93% decrease year-over-year.

BioVie Inc (BIVI) Cash Flow 2024

BIVI recorded a free cash flow (TTM) of -$41.11 million for the quarter ending December 31, 2023, a -41.86% decrease year-over-year.

BioVie Inc (BIVI) Earnings per Share 2024

BIVI earnings per share (TTM) was -$1.17 for the quarter ending December 31, 2023, a +21.48% growth year-over-year.

BioVie Inc Stock (BIVI) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
DO CUONG V	President & CEO	Nov 30 '23	Buy	1.78	10,000	17,800	68,759
GORLIN STEVE	Director	Sep 05 '23	Sale	3.05	8,560	26,108	75,680
BERMAN RICHARD J	Director	Aug 22 '23	Sale	3.50	10,805	37,827	16,789
BERMAN RICHARD J	Director	Jun 07 '23	Sale	5.81	5,984	34,782	23,210
BERMAN RICHARD J	Director	May 22 '23	Sale	6.50	5,000	32,506	29,194

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.